Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Zachary Bloomgarden


Zachary Bloomgarden

Editor, the Journal of Diabetes; Clinical Professor, Icahn School of Medicine at Mount Sinai, USA

Biography

Bloomgarden is a clinician in private practice with an international reputation for writing and lecturing on diabetes, having authored more than 450 articles. He is Clinical Professor at Mount Sinai School of Medicine, and is Editor of the Journal of Diabetes. He served on the Board of the American Association of Clinical Endocrinologists, the Journals Managing Subcommittee of the Endocrine Society, and the Editorial Board of Diabetes Care, and has been principal investigator in numerous studies. In 2012, Dr. Bloomgarden was awarded the title of Master of the American College of Endocrinology. He has been listed for many years in the “Castle Connolly Guide: The Best Doctors New York Metro Area.” Dr Bloomgarden's interests span the overall field of diabetes. He has carefully followed the development of therapeutic approaches over the past two decades, and for many years wrote a renouned monthly commentary in Diabetes Care, entitled "Perspectives on the News," focusing on this and other aspects of clinical care. Currently, as the Editor of the Journal of Diabetes, he writes frequent commentaries spanning various aspects of treatment. He is interested in the epidemiology of diabetes with particular focus on cardiovascular disease, and has paid particular attention to questions of cardiovascular safety and, even more important, to the potential for cardiovascular benefit of diabetes treatment, and he has written on the inapplicability of current FDA recommendations for cardiovascular outcomes to the crucial questions we wish to examine in determining optimal therapeutic approaches. He also is a frequent commentator on novel treatment approaches including insulin treatment modalities, incretin-based treatments, and inhibitors of glucose transport aimed at increasing urinary glucose loss.

Abstract

Abstract : The Future of Diabetes